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Abstract: The association of mutation of the transforming growth factor beta (TGFβ) type II 
receptor (RII) with microsatellite instability revealed a signiﬁ  cant molecular mechanism of 
tumorigenesis and tumor progression in gastrointestinal carcinomas with DNA replication error. 
However, mutation of RII is rare in other types of carcinomas with microsatellite instability 
including endometrial adenocarcinoma suggesting that TGFβ receptor signaling may be neces-
sary for tumor progression. To test this hypothesis, we abrogated TGFβ signaling with ectopic 
expression of a dominant-negative RII (DNRII) in human endometrial carcinoma HEC-1-A 
cells with microsatellite instability. Our study showed that over-expression of DNRII blocked 
the TGFβ signaling, inhibited anchorage-dependent and -independent growth, and stimulated 
apoptosis in vitro. Interestingly, the expression of DNRII expression showed little effect on 
tumor growth of subcutaneously inoculated cells in vivo. On the other hand, the DNRII cells 
showed more epithelial features whereas the control cells showed more mesenchymal features 
suggesting a reversal of autocrine TGFβ-induced epithelial–mesenchymal transition (EMT). 
Consistent with these ﬁ  ndings, DNRII cells were much less migratory and invasive in vitro and 
metastatic in vivo than the control cells. Therefore, an intact TGFβ signaling pathway appears 
necessary for the metastatic phenotypes of this carcinoma model.
Keywords: TGFβ, transforming growth factor β, autocrine TGFβ signaling, human endometrial 
cancer, metastasis, epithelial–mesenchymal transition
Introduction
Transforming growth factor beta (TGFβ) superfamily cytokines regulate diverse 
biological functions including cell proliferation, differentiation, migration, survival and 
apoptosis.1 TGFβ exerts its effect by binding to a heteromeric complex of transmem-
brane serine/threonine kinase, the type I (RI) and type II (RII) receptors. Following 
ligand binding to the RI/RII complex, TGFβ type I receptor phosphorylates Smad2 and 
Smad3, the so called receptor-regulated Smads (R-Smads). Phosphorylated R-Smads 
form heteromeric complex with Smad4 and translocate into the nucleus to regulate 
TGFβ-responsive gene transcription. Multiple Smad-independent pathways have also 
been implicated including MAPK pathways, PI3K pathways, and RhoA.2,3
The role of TGFβ in tumor biology is complex because it can act as both a tumor 
suppressor and a tumor promoter.4,5 TGFβ elicits the tumor suppressor activity by 
potently inhibit the proliferation of epithelial, endothelial and haematopoietic cells. 
However, as tumors evolve, they often evade the TGFβ growth inhibition due to 
mutational inactivation or dysregulated expression of various components of the TGFβ 
signaling pathways or cell cycle regulatory network.6 Several studies demonstrated 
that abrogation of TGFβ signaling with the expression of a dominant-negative type 
II receptor (DNRII) in various tumor cells can impair their motility and tumorigenic-
ity, prevent epithelial–mesenchymal transition (EMT) and reduce their metastatic 
potential,7–12 suggesting that autocrine TGFβ signaling may promote tumor progression. Cancer Management and Research 2009:1 16
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In contrast, DNRII expression increased the skin and 
prostate cancer metastasis.13,14 Clinical studies also showed 
the contradicting data regarding the patient outcome and 
loss of RII in tumor cells.15–17 All these studies suggest the 
effect of TGFβ RII or the effect of autocrine TGFβ activity 
is cell/tissue or stage speciﬁ  c.
Endometrial cancer is the fourth leading cancer and the 
eighth most common cause of cancer death in women in 
the United States. In 2008, an estimated 40,100 women 
in the United States are expected to be diagnosed with 
endometrial cancer, and an estimated 7,470 women are 
expected to die of the disease.18 Most deaths of the cancer 
are caused by metastases that are resistant to conventional 
therapies. Therefore, it is important to study the molecular 
mechanism of endometrial carcinoma metastasis in order 
to gain insight into better therapies. Endometrial cancer 
HEC-1-A cell line is TGFβ-sensitive,19,20 yet it is defective 
in the DNA mismatch repair (MMR) genes hPMS2 and 
hMSH6.21 MMR-gene deﬁ  cient cells are susceptible to pro-
gressive accumulation of alterations at microsatellite loci, 
known as microsatellite instability or RER+ (replication 
error). Because human TGFβ RII coding sequence contains 
a microsatellite sequence, it has been shown to be mutated in 
colon and gastric cancer cells with deﬁ  cient DNA MMR and 
microsatellite instability.22,23 However, mutation of human 
TGFβ RII was found to be rare in endometrial cancer.23 
As a RER+ endometrial cancer cell line, HEC-1-A has an 
operational TGFβ-signaling pathway. Because RII mutation 
is signiﬁ  cantly correlated with longer survival in colon cancer 
patients,16 we hypothesized that TGFβ receptor signaling may 
contribute to the malignant properties of HEC-1-A cells. 
Our study demonstrates that abrogation of TGFβ receptor 
signaling with the expression of either a dominant negative 
RII (DNRII) or a DNRII-EGFP fusion protein in HEC-1-A 
cells induced apoptosis and reduced invasive and metastatic 
potential of the cells suggesting that autocrine TGFβ signal-
ing promotes cell survival and tumor progression.
Materials and methods
Cell line and cell culture
Human endometrial carcinoma cell line HEC-1-A was 
obtained from the American Type Culture Collection and 
cultured in McCoy 5A medium with 10% fetal bovine 
serum (FBS), pyruvate, vitamins, amino acids, and anti-
biotics as previously described.24 One pair of HEC-1-A 
cells was infected with control pLPCX retrovirus vector 
(Clontech, Mountain View, CA, USA) or pLPCX-DNRII, 
which expresses a dominant negative RII without the 
intracellular kinase domain as previously reported.25 
The stably transfected cells were named as control and 
DNRII respectively. Another pair of HEC-1-A cells was 
subsequently infected with the retrovirus vector pLPCX-
EGFP, which expresses the enhanced green ﬂ  uorescence 
protein, or pLPCX-DNRII-EGFP, which expresses a fusion 
protein of the DNRII and EGFP. The stably transfected cells 
were named as control-EGFP and DNRII-EGFP, respec-
tively. It should be noted that the two paired cell lines were 
produced at different times and were not used in various 
experiments at the same time. Therefore, even though the 
data from the two paired cell lines are presented together 
in the Result section, the data from the control and control-
EGFP cannot be compared due to different assay conditions. 
Working cultures were maintained at 37 °C in a humidiﬁ  ed 
incubator with 5% CO2.
Western blot and antibodies
The cells were rinsed two times with ice-cold PBS 
and lysed in cell lysis buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1%Nonidet P-40) containing protease and 
phosphatase inhibitors (EDTA protease inhibitors, 1 mM 
NaVO3 and 1 mM NaF; Boehringer Mannheim GmbH, 
Mannheim, Germany). Equal amounts of protein were 
separated on SDS-PAGE and transferred to a nitrocel-
lulose membrane (Amersham Corp., Louisville, CO, 
USA). Blots were blocked in TBST (100 mM Tris-HCl 
[pH 8.0], 150 mM NaCl, 0.05% Tween-20) containing 5% 
nonfat powder milk. The membrane was then incubated 
with primary antibody for 1 hour at room temperature or 
overnight at 4 °C. Antibodies used were phospho-Smad2 
(Ser 465/467) (Upstate Biotechnology, Waltham, MA, 
USA), total Smad2/3 (BD Transduction Laboratories, 
Lexington, KY, USA), PTEN (Oncogene, Cambridge, 
MA, USA), phospho-Erk, phospho-p38 and phospho-Akt 
(Cell Signaling Technology, Danvers, MA, USA). After 
three washes with TBST, the membrane was incubated 
with HRP-linked secondary antibody (1:3000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) for 1 h at room 
temperature and washed again. Bound complexes were 
detected using chemiluminescence procedures according 
to the manufacturer’s instructions (NEN Life Science 
Products, Boston, MA, USA).
Transient transfection and luciferase assay
To determine the transcription activation by autocrine 
TGFβ activity mediated by Smad3 and Smad4, we 
measured a TGFβ-responsive promoter activity using Cancer Management and Research 2009:1 17
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pSBE4-Luc construct. The promoter activity is reported 
by luciferase activity. Cells were plated in 12-well plates 
and co-transfected with the pSBE4-Luc (0.5 μg) and a 
β-galactosidase expression plasmid (0.1 μg) after 24 h using 
Fugene6 (Roche Molecular Biochemicals, Indianapolis, 
IN, USA) according to the manufacturer’s instructions. 
Two hours later, the cells were treated with or without 
TGFβ3 (1.0 ng/ml). TGFβ3 was used in the study due to its 
availability in our lab. It was shown to induce the same cel-
lular responses as TGFβ in HEC-1-A cells. After another 
24 h, cells were lysed and the activities of luciferase and 
β-galactosidase were assayed as described previously.25 
Luciferase activity was normalized to β-galactosidase activ-
ity and expressed as relative luciferase activity.
Anchorage-dependent growth assays
To study the effect of blockade of autocrine TGFβ signaling 
on cell proliferation on plastic, two growth assays were 
performed. In the ﬁ  rst assay, control-EGFP and DNRII-EGFP 
were plated in 96-well culture plates at 1,000 cells/well and 
treated with different concentrations of TGFβ3. Relative cell 
number in each well was determined ﬁ  ve days after plating 
with MTT assay as described previously.26 In the second 
assay, cells were plated in 96-well plates at 1,000 cells/well 
and treated with or without 1.0 ng/ml TGFβ3. Relative cell 
number was determined with the MTT assay every 48 h after 
plating till day 7.
Soft agarose assay
To determine the effect of blockade of autocrine TGFβ 
signaling on the ability of the cell to grow anchorage-inde-
pendently in a semisolid medium, soft agarose assays were 
performed as described previously.26 Brieﬂ  y, 3 × 103 cells 
were suspended in 1 ml of 0.4% low melting point agarose 
(Life Technologies, Carlsbad, CA, USA) dissolved in the 
regular culture medium and plated on the top of a 1 ml 
underlayer of 0.8% agarose in the same medium in six-well 
culture plates. After four weeks of incubation in the humidi-
ﬁ  ed incubator with 5% CO2 at 37 °C, the cell colonies were 
visualized by staining with 1 ml of p-iodonitrotetrazolium 
violet staining (Sigma, St Louis, MO, USA).
Cell death detection ELISA
DNA fragmentation was measured using the Cell Death 
Detection ELISA kit (Roche Molecular Biochemicals) which 
is based on detection of cytoplasmic histone-associated-DNA-
fragments (mono- and oligonucleosomes). The assay was 
performed as described before.27
Tumorigenicity study
Exponentially growing cultures of HEC-1-A control and 
DNRII were inoculated subcutaneously in both sides of the 
rear ﬂ  ank of ﬁ  ve-week-old female athymic nude mice (Harlan 
Sprague Dawley, Inc., Indianapolis, IN, USA) at 2 × 106 
cells per site. When the growth of tumors was observed, 
each xenograft size was monitored twice a week by exter-
nally measuring tumors in two dimensions using a caliper. 
Xenograft volume (V) was determined by the following 
equation: V = (L × W2) × 0.5, where L is the length and W 
is the width of a xenograft. The use of nude mice for the 
study was approved by our Institutional Animal Care and 
Use Committee.
Immuno-cytochemical staining
Cells were grown on the cover slips in 24-well plate 
till 80% confluence. After the cells were fixed in 2% 
paraformaldehyde, permeablized in 0.1% Triton X-100 and 
blocked with 1.0% bovine serum albumin, the cells were 
incubated with an anti-vimentin (Sigma) or anti-E-cadherin 
(BD Bioscience) antibody for 1 h at room temperature. After 
wash, the cells were incubated with ﬂ  uorescent dye-tagged 
secondary antibody (Alexa Fluor 594; Molecular Probes, 
Carlsbad, CA, USA) in the dark for 1 h at room temperature. 
After wash, the stained cells were covered with a drop of 
mounting medium and a cover slip, sealed with nail polish 
and examined with a confocal ﬂ  uorescence microscope.
Cell migration and invasion assay
Cell migration and invasion was determined by using the 
modiﬁ  ed two-chamber migration assay (8 μm pore size; 
BD Biosciences) or invasion assay (membrane coated with a 
layer of Matrigel extracellular matrix proteins) according to 
the manufacturer’s instructions. Cells were seeded in serum-
free medium into the upper chamber and migrated/invaded 
toward the bottom chamber containing a 10% FBS medium 
with or without 1.0 ng/ml TGFβ3 for 22 hr. Cells in the upper 
chamber were carefully removed using cotton buds and cells 
at the bottom of the membrane were ﬁ  xed and stained with 
HEMA3 Stain Set (Fisher Scientiﬁ  c Company, Pittsburgh, 
PA, USA). Quantiﬁ  cation was performed by counting the 
stained cells on the entire membrane.
In vivo metastasis assay
We performed an experimental lung metastasis assay because 
HEC-1-A cells do not metastasize to lung from subcutaneous 
tumors in the nude mice and lung is a common metastatic 
site in patients with advanced and recurrent endometrial Cancer Management and Research 2009:1 18
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carcinoma.28 Exponentially growing HEC-1-A control-EGFP 
and DNRII-EGFP cells were injected into tail-vein of 
ﬁ  ve-week-old female athymic nude mice (Harlan Sprague 
Dawley, Inc.) at 200,000 cells per mouse. Nine weeks later, 
animals were euthanized, and lungs were removed during 
autopsy for the detection of metastatic colonies by two 
methods. First, the EGFP-expressing green metastatic cancer 
cell colonies were identiﬁ  ed and counted using a Nikon 
ﬂ  uorescence microscope (TE-200; Nikon Corp., Melville, 
NY, USA) with a 20 × objective lens (200 × magniﬁ  cation). 
Then, the lung tissues were ﬁ  xed in Bouin’s solution (Sigma), 
and the metastatic nodules on the surface of the lungs were 
identiﬁ  ed and counted with the aid of a magniﬁ  er.
Statistical analysis
Student t-tests were used to determine the difference between 
control and experimental data.29
Results
Expression of DNRII attenuated TGFβ 
signaling in HEC-1-A cell
Human endometrial cancer cell line HEC-1-A is TGFβ 
sensitive. In this study, a dominant-negative RII (DNRII) 
without the cytoplasmic kinase domain was ﬁ  rst trans-
fected into HEC-1-A cells for the determination of the role 
of TGFβ signaling in their proliferation and apoptosis. 
Later, a EGFP or a DNRII-EGFP fusion protein was also 
ectopically expressed in HEC-1-A cells so that metastatic 
cells can be tracked in vivo. The expression of DNRII or 
DNRII-EGFP was detected with Western immunoblotting 
as shown in Figure 1A. It should be noted that because the 
two paired cell lines were not produced and used at the same 
time for various experiments, the data from the control and 
control-EGFP cannot be compared due to variations in assay 
conditions although the data from the two paired cell lines 
are presented in the same ﬁ  gure. To determine whether the 
expression of DNRII or DNRII-EGFP abrogated TGFβ 
signaling, we ﬁ  rst compared the effect of TGFβ to induce 
the phosphorylation of Smad2 (P-Smad2) in the control 
and DNRII cells. Figure 1B shows that the expression of 
both DNRII and DNRII-EGFP attenuated TGFβ-induced 
P-Smad2 although the relative reduction of P-Smad2 was 
more dramatic in DNRII-EGFP cells than in DNRII cells. 
This is likely in part due to the lower expression level of 
DNRII than DNRII-EGFP as shown in Figure 1A. Consis-
tently, the blockade of Smad phosphorylation also led to 
attenuated stimulation of a TGFβ-responsive promoter activ-
ity by TGFβ in the both DNRII and DNRII-EGFP expressing 
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Figure 1 Effects of DNRII expression on TGFβ signaling in HEC-1-A cells. A) 
Expression of DNRII or DNRII-EGFP were detected with Western immunoblotting. 
GAPDH levels were used to indicate equal sample loading. B) Exponentially growing 
cultures of the indicated cells were treated with 1.0 ng/ml of TGFβ3 for different time 
periods as indicated. Cell lysates were collected for measuring the levels of phosphory-
lated Smad2 (P-Smad2) and total Smad2/3 with Western immunoblotting as described 
in the Materials and methods. (C and D) The indicated cells were plated in 12-well 
plates and transiently transfected with pSBE4-Luc and β-gal constructs with Fugene6. 
The transfected cells were treated with or without 1.0 ng/ml TGFβ3. The activities 
of luciferase and β-gal were measured 24 h later. Luciferase activity was normalized 
to β-gal activity and expressed as relative luciferase unit (RLU). The results plotted 
represent the means ± SEM from triplicate transfections.
Notes: *Denotes signiﬁ  cant (P  0.05) difference between control and its respective 
DNRII cells in the absence of exogenous TGFβ3.
cells (Figures 1C, 1D). It is worth noting that in both pairs of 
HEC-1-A cells, the basal luciferase activity in control cells 
was signiﬁ  cantly (p  0.05) higher than that in DNRII cells 
indicating that the DNRII can antagonize exogenous and 
endogenous/autocrine TGFβ activity in HEC-1-A cells.
Autocrine TGFβ activity supported 
the growth of HEC-1-A cell
The growth of HEC-1-A cells was moderately inhibited by 
TGFβ in a dose-dependent manner by 23% at the highest 
TGFβ concentration (Figure 2A) and in a time-dependent Cancer Management and Research 2009:1 19
Role of TGFβ signaling in endometrial cancer
manner by about 40% on day 7 (Figure 2B). Abrogation of 
TGFβ signaling by the expression of DNRII-EGFP abolished 
the growth inhibitory activity of exogenous TGFβ as shown 
in Figures 2A and 2B. Interestingly, DNRII-EGFP cells 
appeared to grow somewhat slower than control-EGFP cells. 
The slower growth rate of DNRII-EGFP cells was manifested 
when cells were plated on soft agarose. The control-EGFP 
cells formed larger and more colonies than the DNRII-EGFP 
cells did when suspended in soft agarose (Figure 2C). These 
results suggest that autocrine TGFβ appears to support both 
anchorage-dependent and anchorage-independent growth of 
the HEC-1-A cell.
Abrogation of autocrine TGFβ signaling 
induced apoptosis in HEC-1-A cell
The paradoxical observation that both exogenous TGFβ 
treatment and abrogation of autocrine TGFβ signaling 
inhibited the growth of HEC-1-A cells made us to determine 
whether autocrine TGFβ signaling is necessary for the cell 
survival as we observed in other model systems.25,27 Using 
the Cell Death Detection ELISA Assay, we found that both 
DNRII and DNRII-EGFP cells were signiﬁ  cantly more 
apoptotic than their respective controls (Figures 3A, 3B). 
The increased cell death in the DNRII cells was associated 
with a decreased level of phosphorylated/activated Erk and 
Akt (Figure 3C), which are known to be activated by TGFβ 
signaling.2 This is consistent with our previous reports and 
those by others that autocrine TGFβ-induced activation of 
Erk and Akt is necessary for supporting cell survival.25,27,30 On 
the other hand, the levels of phosphorylated p38 and PTEN 
were not affected in this model system even though they 
have been shown to be regulated by TGFβ in other model 
systems27,31 indicating the speciﬁ  city of the altered levels 
of phosphorylated Erk and Akt by the blockade of TGFβ 
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signaling. Taken together, these data indicate a biphasic 
action of TGFβ signaling in the regulation of the survival 
and proliferation of HEC-1-A cells.
DNRII expression had no effect 
on tumorigenicity in vivo
Because the expression of DNRII was able to suppress the 
growth and induce apoptosis in vitro, we next tested whether 
DNRII expression affected the in vivo tumorigenicity of the 
HEC-1-A cell. Exponentially growing cells of the control and 
DNRII cells were inoculated subcutaneously in both sides of 
rear ﬂ  ank of athymic nude mice. Tumor size was monitored 
and measured externally with a caliper. All inoculated sites 
developed tumors in both groups. Furthermore, tumors 
formed by both control and DNRII cells showed a similar 
growth rate as shown in Figure 4. The experiment was 
repeated with the control-EGFP and DNRII-EGFP cells 
and the same results were obtained (data not shown). Thus, 
blockade of TGFβ signaling had no effect on tumor incidence 
and tumor growth rate in this model system.
DNRII expression suppressed EMT, 
migration, and invasion of HEC-1-A cell
Epithelial–mesenchymal transition (EMT) is believed 
to contribute to cancer progression.32,33 TGFβ is known 
to stimulate EMT.34 The HEC-1-A control cells showed 
a low expression of E-cadherin and high expression 
of vimentin indicating the cells had undergone EMT 
(Figure 5). Interestingly, these phenotypes were reversed 
by the expression of DNRII suggesting that the EMT was 
induced by autocrine TGFβ signaling (Figure 5). Because 
EMT is associated with increased cell migration and invasive-
ness, we next examined whether the expression of DNRII 
attenuated the migratory and invasive potential of HEC-1-A 
cells. Using a modiﬁ  ed Boyden chamber assay, we found 
that blockade of autocrine TGFβ signaling signiﬁ  cantly 
inhibited motility of both DNRII (Figure 6A) and DNRII-
EGFP (Figure 6B) cells in comparison with their respective 
controls. Blockade of TGFβ signaling also attenuated the 
invasive potential of the cells through Matrigel as shown 
in Figures 6C and 6D. The expression of DNRII also abro-
gated the stimulation of migration and invasion by exogenous 
TGFβ (Figures 6A–6C).
Effect of blockade of TGFβ signaling 
on the metastasis potential of HEC-1-A 
cell in vivo
The inhibition of EMT, migration, and invasion by the 
abrogation of TGFβ signaling suggested to us that DNRII-
expressing cells might be less metastatic than the control 
cells. Because spontaneous distance metastasis was not 
observed in the mice bearing subcutaneous HEC-1-A tumors, 
the control-EGFP and DNRII-EGFP cells were injected 
intravenously through tail vein into athymic nude mice. This 
experimental lung metastasis assay is particularly relevant 
because TGFβ signaling in mammary tumor cells has been 
shown to promote extravasation in lung35 and lung metastasis 
is observed in endometrial cancer patients.28 Metastasis to 
lung was quantiﬁ  ed by counting green ﬂ  uorescence foci in 
whole lungs with a ﬂ  uorescence inverted microscope as well 
as the number of metastatic nodules on the surface of lungs. 
Figure 5 The effect of DNRII expression on the levels of E-cadherin and vimentin. 
Control-EGFP and DNRII-EGFP cells were grown on cover slips in a 24-well plate till 
80% conﬂ  uence. The cells were ﬁ  xed, permeablized, blocked and incubated with an 
anti-vimentin or anti-E-cadherin antibody for 1 h at room temperature.   After wash, 
the cells were incubated with a ﬂ  uorescent dye-tagged secondary antibody. The stained 
cells were visualized with a confocal ﬂ  uorescence microscope.
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Figure 4 Tumor growth curve of control and DNRII cells in nude mice. Exponentially 
growing control and DNRII cells were inoculated subcutaneously in both sides of 
the rear ﬂ  ank of ﬁ  ve-week-old female athymic nude mice at 2.0 × 106 per inoculum. 
The tumor size was measured with a caliper in two dimensions twice a week after the 
growth of tumors was observed. Tumor volumes were calculated with the equation 
V = (L × W 2) × 0.5, where L is length and W is width of a tumor.   Values are mean ± SEM 
of 12 or 10 tumors formed by control and DNRII cells, respectively.
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This experimental metastasis assay showed that three out of 
ﬁ  ve animals had lung metastasis in the control-EGFP group, 
while two out of ﬁ  ve animals in DNRII-EGFP group had lung 
metastasis. More strikingly, for the mice with lung metastasis, 
the metastasis colonies were much larger (Figure 7A) and 
more in number in every mouse of the control-GFP group 
than that in the DNRII-EGFP group (Figures 7B, 7C). These 
results suggest that TGFβ signaling promotes the metastatic 
potential of HEC-1-A cells in vivo.
Discussion
Mutational inactivation of TGFβ RII has been frequently 
observed in hereditary nonpolyposis colorectal carcinoma 
(HNPCC) cells with a defective DNA mismatch repair system 
and microsatellite instability.36 Paradoxically, RII mutation is 
signiﬁ  cantly rare in endometrial carcinoma with microsatellite 
instability in HNPCC patients.23 Interestingly, RII expression 
was found to be positively, whereas the expression of Smad2 
and Samd4 was found to be negatively, associated with the 
depth of myometrial invasion in endometrial cancer.37 On the 
other hand, reduced expression of TGFβ target genes was 
observed in rat endometrial adenocarcinoma suggesting an 
attenuation of TGFβ signaling during the development of 
the adenocarcinoma.38 Because the TGFβ target genes are 
mostly regulated via Samd pathway, their reduced expres-
sion in the rat endometrial adenocarcinoma could be due 
to the reduced expression of Smad proteins as observed in 
human endometrial carcinoma.37 On the other hand, TGFβ 
binding to its receptors is known to also activate non-Samd 
pathways such as Ras/MAPK and PI3K/AKT pathways.2 
Thus, the attenuation of Smad pathway may enhance the 
tumor-promoting activity of TGFβ through the activation of 
Ras/MAPK and PI3K/AKT pathways. Although TGFβ sig-
naling has been shown to play different, sometimes opposite, 
role in the regulation of tumor progression in different model 
systems, how these different effects are played out by the 
intracellular pathways downstream from its receptors remains 
to be clariﬁ  ed. In this study, we investigated the role of TGFβ 
signaling in the regulation of growth and metastasis of the 
human endometrial carcinoma HEC-1-A cells by targeting 
its signaling at the receptor level. Ectopic expression of both 
DNRII or DNRII-EGFP was shown effective in abrogating 
TGFβ signaling. Blockade of autocrine TGFβ signaling 
induced apoptosis and inhibited cell migration, invasion and 
metastatic potential. Although it is not known whether Smad 
proteins that mediate TGFβ signaling is down-regulated or 
not in HEC-1-A cells, our results suggest that in contrast to 
gastrointestinal tumors, TGFβ receptor signaling appears 
to be retained for the survival and progression of certain 
endometrial cancer cells such as HEC-1-A.
The tumor suppressive activity of TGFβ pathway is 
mainly attributed to its inhibition of cell cycle progression 
from G1 to S phase. Although treatment of HEC-1-A cells 
with exogenous TGFβ was shown to moderately inhibit cell 
proliferation, blockage of TGFβ signaling did not enhance 
cell proliferation, but induced cell apoptosis. This was 
apparently due to the reduced activity of both Erk and Akt 
pathways as both pathways have been shown previously to 
mediate autocrine TGFβ-induced cell survival.25,27 These 
observations suggest a biphasic action of TGFβ signaling 
in which high levels of TGFβ signaling can inhibit cell 
proliferation while very low signaling activity can induce 
cell death. Thus, while the growth potential is reduced in the 
DNRII cell due to increased apoptosis, whether the control 
cell grows at a faster, the same, or slower rate than the DNRII 
cell appears dependent on the concentration of extracellular 
TGFβ as illustrated in Figure 2A. This may explain why 
the control and DNRII cells formed similar size of tumors 
when transplanted in vivo even though the DNRII cells were 
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Figure 6 Effect of DNRII expression on cell migration and invasion. HEC-1-A control 
and DNRII A) or Control-EGFP and DNRII-EGFP B) cells were seeded in serum free 
medium in the upper chamber. Culture medium containing 10% FBS with or without 
1.0 ng/ml TGFβ3 was added in the lower chamber.   To test the invasive potential, 
HEC-1-A control-EGFP and DNRII-EGFP cells C) were plated in serum free medium 
onto the upper chamber coated with a layer of Matrigel.   After incubation of 20 h for 
panel A and 24 h for panel B, the cells on the top of the upper chamber membrane 
were removed. The migrated or invaded cells on the bottom of the membrane were 
stained with HEMA3 and visualized under a microscope.   A representative example 
is shown in panel D. Quantiﬁ  cation was performed by counting the stained cells on 
each membrane. Values are means ± SME from three chambers.Cancer Management and Research 2009:1 22
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more apoptotic in vitro, because tumorigenesis is invariably 
associated with increased levels of active TGFβ isoforms in 
the tumor microenvironment.5 The increased TGFβ signal-
ing may inhibit the growth of control cell-formed tumors, 
but not the growth of DNRII cell-formed tumors resulting 
in a similar growth rate between the control and DNRII cell-
formed tumors. On the other hand, the DNRII cell-formed 
tumors may be restrained by increased cell death resulting in 
the similar growth rate as the control tumors. Alternatively, 
the reason that the increased apoptosis in the DNRII cells 
in vitro did not translate into slower tumor growth in vivo 
may be due to gain of cell survival signal from tumor stromal 
cells in vivo.
Previous studies with TGFβ inhibitors such as soluble 
receptors and RI kinase inhibitors showed that systemic 
administration of these inhibitors had limited to no effect 
on the growth of orthotopic tumors in mouse mammary 
glands, but signiﬁ  cantly inhibited pulmonary and skeletal 
metastasis.39–41 These observations are consistent with the 
result that blockade of TGFβ signaling showed little effect 
on the tumorigenicity of HEC-1-A cells and suggest that 
the tumor-promoting activity of TGFβ mainly resides in 
the support of metastasis, which results from increased cell 
migration, invasion, and survival.
Although many signaling pathways have been implicated 
in the regulation of cell migration and invasion, TGFβ is 
known to be a major modulator of tumor cell migration1 
and invasion,42 partly due to its promotion of EMT.43 It is 
believed that during cancer progression, EMT was associated 
speciﬁ  cally with tumor invasiveness and metastasis.44 EMT 
can be stabilized by autocrine TGFβ signaling.45 Both 
in vitro experiments with DNRII cell lines9,46 and in vivo 
experiments with DNRII xenograft tumors10 demonstrated 
that DNRII prevents TGFβ-mediated EMT. Conversely, 
treatment with TGFβ rendered Ras-transformed epithe-
lial cells ﬁ  broblastoid and invasive, and producing more 
endogenous TGFβ, leading to autocrine maintenance of the 
invasive phenotype and recruitment of additional cells to 
become ﬁ  broblastoid and invasive.47 A more recent report 
showed that DNRII expression abrogated TGFβ mediated 
EMT in a transgenic mouse model.48 Consistent with these 
reports, our study showed that DNRII expression reversed 
the EMT in HEC-1-A cells. In addition, DNRII expression 
suppressed the cell migration and invasiveness.
The stimulation of cell migration by TGFβ has been 
shown to be mediated by both Smad-dependent and Smad-
independent pathways including MAP kinase and Akt path-
ways.3,7,49,50 Thus, the reduced levels of activated Erk and Akt 
in our study are consistent with the reduced cell migration 
and invasiveness. Approximately, 90% of colon cancers 
with microsatellite instability have inactivating mutations of 
RII.51 RII mutation is signiﬁ  cantly correlated with favorable 
chemotherapy treatment outcome and longer patient survival 
in colon cancer patients suggesting that complete loss of RII 
in carcinomas may limit systemic metastases.16 Our results 
from the experimental metastasis assay also support this 
proposition. These observations point to the potential util-
ity of TGFβ/receptor inhibitors for the treatment of certain 
advanced endometrial carcinomas as this strategy has been 
implicated as a potential novel treatment modality in late 
stage of other carcinomas.52
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